Cargando…

Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial

BACKGROUND: Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bulluck, Heerajnarain, Fröhlich, Georg M, Nicholas, Jennifer M, Mohdnazri, Shah, Gamma, Reto, Davies, John, Sirker, Alex, Mathur, Anthony, Blackman, Daniel, Garg, Pankaj, Moon, James C, Greenwood, John P, Hausenloy, Derek J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mosby 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483973/ https://www.ncbi.nlm.nih.gov/pubmed/30893577 http://dx.doi.org/10.1016/j.ahj.2019.02.005

Ejemplares similares

Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST‐Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design
por: Bulluck, Heerajnarain, et al.
Publicado: (2015)

Incidence of left ventricular thrombi in reperfused STEMI patients detected by contrast-enhanced CMR
por: Bulluck, Heerajnarain, et al.
Publicado: (2015)

High-sensitivity Troponin-T levels in reperfused STEMI patients: A comparison with CMR
por: Ramlall, Manish, et al.
Publicado: (2016)

Chronic iron deposit and left ventricular remodeling in reperfused STEMI patients
por: Bulluck, Heerajnarain, et al.
Publicado: (2016)

Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials
por: Bulluck, Heerajnarain, et al.
Publicado: (2016)

Diagnostic performance of T (1) and T (2) mapping to detect intramyocardial hemorrhage in reperfused ST‐segment elevation myocardial infarction (STEMI) patients
por: Bulluck, Heerajnarain, et al.
Publicado: (2017)

T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients
por: Bulluck, Heerajnarain, et al.
Publicado: (2015)

Circadian variation in acute myocardial infarct size assessed by cardiovascular magnetic resonance in reperfused STEMI patients
por: Bulluck, Heerajnarain, et al.
Publicado: (2017)

Coronary Microvascular Injury in Reperfused Acute Myocardial Infarction: A View From an Integrative Perspective
por: Sezer, Murat, et al.
Publicado: (2018)

Reducing myocardial infarct size: challenges and future opportunities
por: Bulluck, Heerajnarain, et al.
Publicado: (2016)

Left ventricular remodeling after reperfused acute myocardial infarction: insights from automated ECV mapping
por: Bulluck, Heerajnarain, et al.
Publicado: (2016)

Quantification of both the area-at-risk and acute myocardial infarct size in ST-segment elevation myocardial infarction using T1-mapping
por: Bulluck, Heerajnarain, et al.
Publicado: (2017)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Hybrid PET/MR metabolic imaging of the reperfused infarct - new biology, future directions
por: White, Steven K, et al.
Publicado: (2015)

Age and Surgical Complexity impact on Renoprotection by Remote Ischemic Preconditioning during Adult Cardiac Surgery: A Meta analysis
por: Zhou, Chenghui, et al.
Publicado: (2017)

Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segment–Elevation Myocardial Infarction and Adverse Left Ventricular Remodeling
por: Bulluck, Heerajnarain, et al.
Publicado: (2016)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Post–Reperfused ST‐Elevation Myocardial Infarction
por: Bulluck, Heerajnarain, et al.
Publicado: (2016)

Myocardial Infarct Size by CMR in Clinical Cardioprotection Studies: Insights From Randomized Controlled Trials
por: Bulluck, Heerajnarain, et al.
Publicado: (2017)

Impact of microvascular obstruction on semiautomated techniques for quantifying acute and chronic myocardial infarction by cardiovascular magnetic resonance
por: Bulluck, Heerajnarain, et al.
Publicado: (2016)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists in cardiovascular translational biology
por: Chilton, Robert J., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy
por: Gergely, Róbert, et al.
Publicado: (2020)

Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade
por: Jadhav, Uday, et al.
Publicado: (2023)

Minimizing Ischemia Reperfusion Injury in Xenotransplantation
por: Patel, Parth M., et al.
Publicado: (2021)

Sequential Wnt Agonist Then Antagonist Treatment Accelerates Tissue Repair and Minimizes Fibrosis
por: Tian, Xiao-Jun, et al.
Publicado: (2020)

Redefining viability by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction
por: Bulluck, Heerajnarain, et al.
Publicado: (2017)

2414: Reperfusion strategies when non-stemi is misclassified as stemi myocardial infarction
por: Altieri, Pablo I., et al.
Publicado: (2018)

Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy
por: Chin, Eric K, et al.
Publicado: (2015)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Interrogation of the infarcted and salvaged myocardium using multi-parametric mapping cardiovascular magnetic resonance in reperfused ST-segment elevation myocardial infarction patients
por: Hausenloy, Derek J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pnnvm6jlrmhe1130fqmu95pj6o